Viral clearance is critical in the development of monoclonal antibodies, recombinant proteins and glycoproteins, tissue and blood-derived products and medical devices. Viral contamination usually comes from the use of cell lines, tissue sources or raw materials of animal origin. The ICH Q5A Regulatory Guidelines recommend that biopharmaceutical products for human use should ensure that their products' safety is not affected by potential contaminants.
https://www.creative-biolabs.com/immuno-oncology/viral-clearance-studies.htm
